BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1716588)

  • 1. The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis.
    Bowen D; Ehmer B; Neubert P; Lewis T; Jacobs A
    Exp Hematol; 1991 Aug; 19(7):613-6. PubMed ID: 1716588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
    Musto P; Modoni S; Alicino G; Savino A; Longo A; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G
    Haematologica; 1994; 79(6):493-9. PubMed ID: 7896207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters.
    Bowen DT; Culligan D; Beguin Y; Kendall R; Willis N
    Leukemia; 1994 Jan; 8(1):151-5. PubMed ID: 8289479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
    Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
    Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
    Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
    Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin for treatment of myelodysplastic syndromes.
    Rafanelli D; Grossi A; Longo G; Vannucchi AM; Bacci P; Ferrini PR
    Leukemia; 1992 Apr; 6(4):323-7. PubMed ID: 1588794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The erythropoietic effects of interleukin 6 and erythropoietin in vivo.
    Ulich TR; del Castillo J; Yin SM; Egrie JC
    Exp Hematol; 1991 Jan; 19(1):29-34. PubMed ID: 1989892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian rhythm of serum erythropoietin in myelodysplastic syndromes.
    Pasqualetti P; Collacciani A; Casale R
    Eur Rev Med Pharmacol Sci; 2000; 4(5-6):111-5. PubMed ID: 11710507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
    Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
    Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
    Marques da Costa R
    Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful treatment of prolonged anemia after major ABO incompatible bone marrow transplantation for a case of myelodysplastic syndrome with recombinant erythropoietin].
    Koda K; Hayashi S; Ikeda K; Morita K; Tsuji Y; Takimoto R; Fujisaki Y; Nakazawa O
    Rinsho Ketsueki; 1992 Jul; 33(7):991-3. PubMed ID: 1507422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia.
    Bowen D; Hyslop A; Keenan N; Groves M; Culligan D; Johnson P; Shaw A; Geddes F; Evans P; Porter J; Cavill I
    Haematologica; 2006 May; 91(5):709-10. PubMed ID: 16670077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.
    Musto P; Matera R; Minervini MM; Checchia-de Ambrosio C; Bodenizza C; Falcone A; Carotenuto M
    Haematologica; 1994; 79(3):265-8. PubMed ID: 7926977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.
    Herrmann F; Mertelsmann R; Lindemann A; Ottmann OG; Seipelt G; Oster W; Hoelzer D; Ganser A
    Biotechnol Ther; 1991; 2(3-4):299-311. PubMed ID: 1845132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes.
    Bowen DT; Jacobs A; Cotes PM; Lewis TC
    Eur J Haematol; 1990 Jan; 44(1):30-2. PubMed ID: 2307217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
    Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P
    Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of indicators of erythropoiesis stimulated by recombinant human erythropoietin in renal anemia.
    Schmidt G; Stamminger G; Daniel A; Gross J; Syllm-Rapoport I; Lun A; Zoellner K
    Biomed Biochim Acta; 1990; 49(2-3):S275-9. PubMed ID: 2386517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports.
    Valent P
    Leuk Res; 2008 Sep; 32(9):1333-7. PubMed ID: 18417212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.